Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : ARADIGM CORP. ARDM -- Ignore unavailable to you. Want to Upgrade?

To: tnsaf who wrote (23)	12/7/1998 3:22:00 PM
From: shoe	Read Replies (1) \| Respond to of 255

To All: Finally some news on Aradigm: Warburg Dillon Read issued a Company Report on December 10, 1997 for Aradigm Corporation. On December 10, 1997 Warburg Dillon Read analyst Andrew Foreman issued a 3 page Company Report on Aradigm Corporation. Report highlights: 'Coverage was initiated with a BUY rating based on the company's expertise at blending pulmonary physiology expertise with state-of-the art device engineering. The 12- to 18-month price target was set at $22. The 1998 EPS estimate was set at a loss of ($0.81). The company was reported to be developing products in the areas of asthma, severe pain, and diabetes.' Report No.: N0086760 Inhale Pharmaceuticals is in the news lately. Wonder what's going on with Aradigm. They don't even have a website!